DE60208854D1 - Attenuierte rekombinante stabile Tollwutvirusmutanten und Lebendimpfstoffe - Google Patents

Attenuierte rekombinante stabile Tollwutvirusmutanten und Lebendimpfstoffe

Info

Publication number
DE60208854D1
DE60208854D1 DE60208854T DE60208854T DE60208854D1 DE 60208854 D1 DE60208854 D1 DE 60208854D1 DE 60208854 T DE60208854 T DE 60208854T DE 60208854 T DE60208854 T DE 60208854T DE 60208854 D1 DE60208854 D1 DE 60208854D1
Authority
DE
Germany
Prior art keywords
rabies virus
live vaccines
attenuated recombinant
virus mutants
recombinant stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60208854T
Other languages
English (en)
Other versions
DE60208854T2 (de
Inventor
T Mebatsion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of DE60208854D1 publication Critical patent/DE60208854D1/de
Application granted granted Critical
Publication of DE60208854T2 publication Critical patent/DE60208854T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60208854T 2001-04-23 2002-04-17 Attenuierte rekombinante stabile Tollwutvirusmutanten und Lebendimpfstoffe Expired - Lifetime DE60208854T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01201464 2001-04-23
EP01201464 2001-04-23
EP01203773 2001-10-05
EP01203773 2001-10-05

Publications (2)

Publication Number Publication Date
DE60208854D1 true DE60208854D1 (de) 2006-04-13
DE60208854T2 DE60208854T2 (de) 2006-08-17

Family

ID=26076884

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60208854T Expired - Lifetime DE60208854T2 (de) 2001-04-23 2002-04-17 Attenuierte rekombinante stabile Tollwutvirusmutanten und Lebendimpfstoffe

Country Status (10)

Country Link
US (1) US6887479B2 (de)
EP (1) EP1253197B1 (de)
AR (1) AR033873A1 (de)
AT (1) ATE316572T1 (de)
BR (1) BR0201366A (de)
CA (1) CA2382993A1 (de)
DE (1) DE60208854T2 (de)
ES (1) ES2257505T3 (de)
PT (1) PT1253197E (de)
TR (1) TR200201081A3 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51371B (en) * 2004-07-12 2011-02-28 Thomas Jefferson University, Office Of Technology Transfer MIXTURES OF RECOMBINANT RABIJES VIRUS
WO2007047459A1 (en) 2005-10-14 2007-04-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus vector systems and compositions and methods thereof
CN104059890A (zh) * 2005-12-14 2014-09-24 乔治亚大学研究基金公司 狂犬病疫苗
FR2944292B1 (fr) 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
WO2011163446A2 (en) * 2010-06-24 2011-12-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pan-lyssavirus vaccines against rabies
EP2670843B1 (de) 2011-02-03 2014-10-29 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Multivalente impfstoffe für tollwutvirus und filoviren
EP4104854A3 (de) 2016-04-04 2023-03-08 The United States of America as represented by the Secretary of the Department of Health and Human Services Multivalente impfstoffe gegen tollwutvirus und coronaviren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE356202T1 (de) * 1998-11-27 2007-03-15 Intervet Int Bv Attenuierte stabile tollwutvirusmutante und lebende impfstoffe

Also Published As

Publication number Publication date
AR033873A1 (es) 2004-01-07
EP1253197B1 (de) 2006-01-25
EP1253197A1 (de) 2002-10-30
ES2257505T3 (es) 2006-08-01
TR200201081A2 (tr) 2002-11-21
US6887479B2 (en) 2005-05-03
ATE316572T1 (de) 2006-02-15
CA2382993A1 (en) 2002-10-23
US20020164356A1 (en) 2002-11-07
DE60208854T2 (de) 2006-08-17
BR0201366A (pt) 2003-06-10
PT1253197E (pt) 2006-06-30
TR200201081A3 (tr) 2002-11-21

Similar Documents

Publication Publication Date Title
CY2016018I1 (el) Εμβολιο κατα του ιου του δυτικου νειλου
DE69923434D1 (de) Adjuvierte rekombinante Lebendimpfstoffe gegen Influenza- oder Herpesviren
DK1390066T3 (da) Vaccinesammensætning
FR14C0016I2 (fr) Vacccin west nile
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
AU4932601A (en) Recombinant parainfluenza virus expression systems and vaccines
NO20021786D0 (no) Skumdempningsfremgangsmåter og sammensetninger
EP1575601A4 (de) Rekombinanteimpfstoffviren, die il-15 exprimieren, sowie verfahren zu ihrer verwendung
IL200747A0 (en) Subunits of the enteritis hemorrhagic virus fiber protein and uses thereof as vaccines
EP1497654A4 (de) Immunoglobulin-e-vakzine und verwendungsverfahren dafür
NO20030239D0 (no) Modifisert virus
NO20040995L (no) Subenhetsvaksine for smittsom bukspyttkjertel-nekrosevirus
DK1749885T3 (da) Infektiøs og svækket kvægdiarévirus
IL157251A0 (en) Hepatitis b virus treatment
DK2116257T3 (da) Parenterale vaccineformuleringer og anvendelser deraf
DE60208854D1 (de) Attenuierte rekombinante stabile Tollwutvirusmutanten und Lebendimpfstoffe
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
EP1651258A4 (de) Hepatitis virus kern-proteine als vakzine-plattformen und anwendungsverfahren dafür
ATE356202T1 (de) Attenuierte stabile tollwutvirusmutante und lebende impfstoffe
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
DE60226057D1 (de) Geflügelkrankheit verursachendes bakterium und daraus stammender impfstoff
IL149173A0 (en) Attenuated recombinant rabies virus mutants and live vaccines thereof
DK1180041T3 (da) Vaccine med ISA-virus
DK2258850T3 (da) Rekombinante virusbaserede malariavacciner
GB0023445D0 (en) Attenuated virus vaccine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: INTERVET INTERNATIONAL B. V., AN BOXMEER, NL